An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
about
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsEpidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issuesNew molecularly targeted therapies for lung cancerReview of the current targeted therapies for non-small-cell lung cancerStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerAllelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domainGefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimeticsBIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsMET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agentsGene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.Development and Evaluation of 18F-IRS for Molecular Imaging Mutant EGF Receptors in NSCLC.Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma.Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutationInhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachErlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.Differential sensitivity of ERBB2 kinase domain mutations towards lapatinibTargeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.β-catenin contributes to lung tumor development induced by EGFR mutationsEGFR-mutated lung cancer: a paradigm of molecular oncology.HeurAA: accurate and fast detection of genetic variations with a novel heuristic amplicon aligner program for next generation sequencing.Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common featuresNVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation.Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesButein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cellsTargetable "driver" mutations in non small cell lung cancer.Heat shock protein 90 inhibition in lung cancer.Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.Molecular chess? Hallmarks of anti-cancer drug resistanceFirst-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.Update in lung cancer 2005.
P2860
Q24646295-5C4E40A0-4C66-4ED2-B304-1AD805AE0499Q24649935-A0CF63FE-CE9F-4683-BE38-B2735CA33303Q24653036-11051179-B08A-4F62-BD63-D0284C359BC9Q24680988-AD2295CA-38BF-4B26-97F6-29687A1C3DEEQ27015079-B6B695C2-3F37-4656-9E4F-E22B5E4FE299Q27680966-96CC388D-7A4B-4B0C-9D26-E6A13C041690Q27851396-660B406E-7221-42C7-868A-5BD0594F36CEQ27865182-5259888C-47A7-4642-B6BF-6DC7BFA32749Q28469345-AC24A0E6-C085-49BE-BE2F-78C55F6BE6F1Q28756824-271BDC7D-395A-43B7-A952-3C17E19132C6Q30502341-21D7F1F9-A08B-4139-9C6D-7EAF0A542E52Q33263277-028C502C-D8B4-4A5C-92AE-7F213054A679Q33759715-2D0AF7C8-EF1F-4712-8B6A-BE968F67C897Q33784735-08268319-33A7-4158-97BD-21B39A71740DQ33788708-8E01A458-1ACE-41C3-8170-FED261B92928Q33901617-CCE308BB-48FC-4D19-8B6D-8EC7B461F514Q33902463-E3F46701-EEF8-4FA1-B355-E30F938A6323Q33925323-D302B761-FCC9-43DD-81F1-1C71326EE29AQ33945734-8EFA3994-38C9-4359-B145-8C9C94749F35Q34064653-7A86C0A6-D025-45E7-B5C2-926C4B641918Q34205052-25DF7A3E-AA59-40B3-8E25-686EA1714E5CQ34353437-DA107C31-46AB-45E4-A1E8-C1A8EEEDC4F5Q34406334-BEF9B1CE-A357-4A99-BF3F-4497CCC7B7F7Q34562884-5EE79C1C-D463-47E4-942E-CD8E30F00545Q34772704-391DB4F8-0431-4AE8-9A9C-760AFF8CD39EQ34976925-705385D1-136B-4CCF-9CFE-A26E55C8ED0DQ35063769-DF8BAAC2-D36E-4B9B-9DB6-4220F080DD66Q35081010-EF3A5438-EFC4-4F43-B3D5-A83B881A8538Q35146927-9E88C08B-6D04-4F04-A073-2F96C3E88892Q35196999-E41F74A5-5D99-44F5-83C0-3F2F23349649Q35449387-D938BE0C-CBBE-41C3-A8A5-E833351673D0Q35589285-5089A635-EBE0-467E-A185-ABC710466882Q35623056-2063BE3C-B2FB-4A63-828F-855E498F8A96Q35737325-547DDB5F-45A2-4661-AA39-106C033062C1Q35762499-EF3611A4-BC1E-4BE8-B387-9C14A6667E78Q35994416-A718700F-A692-404A-88C4-F35263B16DC3Q36240941-76335F88-49B5-4526-ADAD-049CD900D41AQ36283596-7E034380-1DE9-4517-B564-DC45AA2462BEQ36427381-F4E1CF4C-583D-4F47-AE5A-C05DDFEAE9F0Q36429911-C363B67B-5CC9-4D96-B0E6-4CE9F431D8B2
P2860
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
An alternative inhibitor overc ...... dermal growth factor receptor.
@en
type
label
An alternative inhibitor overc ...... dermal growth factor receptor.
@en
prefLabel
An alternative inhibitor overc ...... dermal growth factor receptor.
@en
P2093
P1433
P1476
An alternative inhibitor overc ...... idermal growth factor receptor
@en
P2093
Balázs Halmos
Hongbin Ji
Matthew Meyerson
Susumu Kobayashi
P304
P356
10.1158/0008-5472.CAN-05-1346
P407
P577
2005-08-01T00:00:00Z